Identification and clinical application for the role of NKT cells in patients with chronic hepatitis and hepatocellualr carcinoma infected hepatitis virus

NKT细胞在肝炎病毒感染的慢性肝炎及肝癌患者中的作用鉴定及临床应用

基本信息

  • 批准号:
    15390236
  • 负责人:
  • 金额:
    $ 9.09万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    2003
  • 资助国家:
    日本
  • 起止时间:
    2003 至 2005
  • 项目状态:
    已结题

项目摘要

Natural killer T (NKT) cells share features of both classical T cells and NK cells. NKT cells are heterogenous populations, and recognize glycolipids associated with CD1d molecule. We investigated Th1/Th2 cytokine production as well as frequency and phenotype of circulating NKT cells in patients with chronic hepatitis (CH) and hepatocellular carcinoma (HCC) infected with hepatitis C virus (HCV). Peripheral blood mononuclear cells (PBMC) were obtained befor and 2 weeks later IFN/ribavirin and radiofrequency ablation therapy for CH and HCC, respectively. PBMC were cultured with α galactosylceramide (α GalCer) and IL-2. Frequency and cytokine production of NKT cells were analyzed with flow cytometry. IFN-γ production of Vα 24+CD3+ T cells did not differ among groups, but became greater after treatment in contrast to lowered IL-4 production.The function of dendritic cells (DCs) appears to be decreased in patients with chronic hepatitis C. However, we have no strategy to modulate its functi … More on. Thus we wanted to induce maturated DC by activating V α 24+ NKT cells. We cultured peripheral blood CD14+ cells in the presence of GMCSF and IL-4. Simultaneously CD3+ T cells were cultured with α GalCer + IL-2. After 5-day culture, they are mixed and cultured with GMCSF, α GalCer and IL-2 for further 2 days. This method induced matured, functional DC.Cytotoxic T lymphocyes (CTLs) are thought to be major effectors for clearing viruses in acute infections including hepatitis B virus (HBV). Persistent HBV infection is characterized by a lack of or a weak CTL response to HBV, which is thought to reflect tolerance to HBV antigens. We found that α GalCer, a ligand for V α 14+ NKT cells in mice, strongly enhanced the induction and proliferation of HBV-specific CTLs by HBsAg. In HbsAg transgenic mice, which are thought to be tolerant to HBV-encoded antigens, administration of HbsAg or α GalCer alone failed to HbsAg-specific CTLs, but they were induced by administration of both compounds. A blocking experiment using antibodies to cytokines and CD4O ligand showed that IL-2 mediates the enhancement of CTL induction caused by α GalCer through NKT activation. Less
天然杀伤T(NKT)细胞具有经典T细胞和NK细胞的特征。 NKT细胞是异质种群,并且识别与CD1D分子相关的糖脂。我们研究了慢性肝炎(CH)和肝细胞癌(HCC)感染丙型肝炎病毒(HCV)的慢性肝炎(CH)和肝细胞癌(HCV)患者的TH1/TH2细胞因子的产生以及循环NKT细胞的频率和表型。分别为CH和HCC的IFN/Ribavirin和Radiofrequency消融疗法获得外周血单核细胞(PBMC)。将PBMC用α甲乳糖基酰胺(αGalcer)和IL-2培养。通过流式细胞仪分析NKT细胞的频率和细胞因子的产生。 Vα24+ CD3+ T细胞的IFN-γ产生在组之间没有差异,但与IL-4的产生相比,治疗后变得更大。树突状细胞(DC)的功能(DC)在慢性丙型肝炎患者中似乎有所改善。但是,我们没有调节其功能的策略。我们想通过激活Vα24+NKT细胞来诱导成熟的DC。在GMCSF和IL-4存在下,我们培养了外周血CD14+细胞。同时用αGalcer + IL-2培养CD3 + T细胞。 5天培养后,将它们与GMCSF,αGalcer和IL-2一起培养2天。这种方法诱导的成熟,功能性DC。胞毒性T淋巴细胞(CTL)被认为是清除包括丙型肝炎病毒(HBV)的急性感染病毒的主要作用。持续性HBV感染的特征是缺乏对HBV的CTL反应,这被认为反映了对HBV抗原的耐受性。我们发现,小鼠中Vα14+NKT细胞的配体αGalcer强烈增强了HBSAG对HBV特异性CTL的诱导和增殖。在HBSAG转基因小鼠中,被认为对HBV编码的抗原具有耐受性,单独使用HBSAG或αgalcer的抗原无法使用HBSAG特异性CTL,但它们是通过两种化合物的给药而诱导的。使用对细胞因子和CD4O配体抗体的阻断实验表明,IL-2介导了通过NKT激活引起的αgalcer引起的CTL诱导的增强。较少的

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The efficacy and safety of thymosin α1 in Japanese patients with chronic hepatitis B ; results of a randomized clinical trial.
胸腺肽α1对日本慢性乙型肝炎患者的疗效和安全性;一项随机临床试验的结果。
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Iino S;Toyota J;Kumada H;et al.
  • 通讯作者:
    et al.
Sugauchi F, et al.: "Epidemiologic and virologic characteristics of hepatitis B virus genoype B having the recombination with genotype C"Gastroenterology. 124. 925-932 (2003)
Sugauchi F 等人:“与基因型 C 重组的乙型肝炎病毒基因型 B 的流行病学和病毒学特征”胃肠病学。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Kasahara S, et al.: "Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes"J Virol. 77. 2469-2477 (2003)
Kasahara S 等人:“缺乏肿瘤坏死因子 α 会导致乙型肝炎病毒特异性细胞毒性 T 淋巴细胞增殖受损”J Virol。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Continued ribavirin monotherapy following interferon-ribavirin combination therapy is not effective for chronic hepatitis C.
干扰素-利巴韦林联合治疗后继续利巴韦林单药治疗对慢性丙型肝炎无效。
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Dohmen K;Mizuta T;Ishibashi H;et al.;Kakumu S.
  • 通讯作者:
    Kakumu S.
Changes in natural killer T cell subsets during therapy in type C hepatitis and hepatocellular crcinoma.
丙型肝炎和肝细胞癌治疗期间自然杀伤 T 细胞亚群的变化。
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Okumura A;Ishikawa T;Maeno T;et al.
  • 通讯作者:
    et al.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KAKUMU Shinichi其他文献

KAKUMU Shinichi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KAKUMU Shinichi', 18)}}的其他基金

To clarify the mechanism of chronicity and to explore therapeutic approach for viral hepatitis
阐明病毒性肝炎慢性机制并探索治疗途径
  • 批准号:
    12670529
  • 财政年份:
    2000
  • 资助金额:
    $ 9.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Pathologicl significance and its inhibition of apoptosis on the development and its progression of liver injury.
细胞凋亡对肝损伤发生发展的病理意义及其抑制作用。
  • 批准号:
    10470142
  • 财政年份:
    1998
  • 资助金额:
    $ 9.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B).
IMMUNO-PATHOGENESIS AND-THERAPY OF VIRAL HEPATITIS
病毒性肝炎的免疫发病机制和治疗
  • 批准号:
    09044341
  • 财政年份:
    1997
  • 资助金额:
    $ 9.09万
  • 项目类别:
    Grant-in-Aid for international Scientific Research
Cellular immune response against HBV nucleocapsid antigen
针对 HBV 核衣壳抗原的细胞免疫反应
  • 批准号:
    07457593
  • 财政年份:
    1995
  • 资助金额:
    $ 9.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Cellular immune response to core region protein of hepatitis C virus in patients with chronic hepatitis C
慢性丙型肝炎患者对丙型肝炎病毒核心区蛋白的细胞免疫反应
  • 批准号:
    05454245
  • 财政年份:
    1993
  • 资助金额:
    $ 9.09万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (B)
Analysis of immunological mechanisms for antibody production to hepatitis B surface antigen.
乙型肝炎表面抗原抗体产生的免疫机制分析。
  • 批准号:
    60570317
  • 财政年份:
    1985
  • 资助金额:
    $ 9.09万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似国自然基金

Galectin-3调控PD-L1在原发性肝细胞癌免疫治疗和预后中的作用及机制
  • 批准号:
    82304216
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
AhR通过增强CPT1A活性介导脂代谢变化促进肝细胞癌进展的机制研究
  • 批准号:
    82302892
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
32P-可降解微球调控TAM-FABP1细胞群的脂质代谢对肝细胞癌免疫微环境的影响及机制
  • 批准号:
    82372065
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
TRIM15-HAT1信号轴激活AGK调控肝细胞癌对酪氨酸激酶抑制剂敏感性的作用机制研究
  • 批准号:
    82373189
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
双重CRISPR dCas9干扰/激活技术靶向再激活X连锁抑癌基因在肝细胞癌性别差异及性别特异性靶向治疗中的作用
  • 批准号:
    82303116
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Impact of sarcopenia and creation of novel therapeutic targets by immunotherapeutic resistance mechanisms in hepatocellular carcinoma
肌少症的影响以及通过免疫治疗耐药机制创建新的治疗靶点对肝细胞癌的影响
  • 批准号:
    23K08106
  • 财政年份:
    2023
  • 资助金额:
    $ 9.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of transcatheter arterial embolization for controlling hypoxia in hepatocellular carcinoma
经导管动脉栓塞控制肝细胞癌缺氧的研究进展
  • 批准号:
    23K07075
  • 财政年份:
    2023
  • 资助金额:
    $ 9.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Dissecting the roles of iron and hemojuvelin in hepatocellular carcinoma
剖析铁和血幼素在肝细胞癌中的作用
  • 批准号:
    478251
  • 财政年份:
    2023
  • 资助金额:
    $ 9.09万
  • 项目类别:
    Operating Grants
Quantitative ultrasound to improve detection and diagnosis of liver cancer
定量超声改善肝癌的检测和诊断
  • 批准号:
    490038
  • 财政年份:
    2023
  • 资助金额:
    $ 9.09万
  • 项目类别:
    Operating Grants
Determinants of immunotherapy response in NASH-Hepatocellular carcinoma
NASH-肝细胞癌免疫治疗反应的决定因素
  • 批准号:
    10735947
  • 财政年份:
    2023
  • 资助金额:
    $ 9.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了